Fig. 2From: On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlatesForest plot of the derived neutrophil-to-lymphocyte ratio on survival outcomes (N = 221). A, B Forest plot of the dNLR on progression-free survival (A) and overall survival (B) in the exploratory cohort. CI, confidence interval; dNLR, derived neutrophil-to-lymphocyte ratio; HR, hazard ratio; OS, overall survival; PFS, progression-free survivalBack to article page